Navigation Links
Rabbit Anti-mTOR Monoclonal Antibody,, Clone ZMD.414 from Invitrogen

ProductsRabbit Anti-mTOR Monoclonal Antibody, Clone ZMD.414 from Invitrogen
Company Invitrogen
Item Rabbit Anti-mTOR Monoclonal Antibody,, Clone ZMD.414
Price 
Description Clone/PAD: ZMD.414. Immunogen: Synthetic peptide derived from an internal region of human mouse and rat mTOR (Mammalian target of rapamycin FRAP RAFT1 RAPT1). Specificity: Specific for the human mTOR protein. On Western blots it identifies the target band at ~235 kDa. Reactivity: Human (positive control: HEK293 cell lysates). Based on sequence homology reactivity with mouse and rat is expected. Applications: Immunoprecipitation Western blotting
Info InvitrogenInvitrogen
Invitrogen Corporation
1600 Faraday Ave.
Carlsbad, CA 92008

Call Invitrogen to buy products (US and Canada only; other locations use numbers below)
USA Canada 1-866-521-4270
Customer Service: 800-955-6288
Tech Support: 800-955-6288 ext. 2
Fax Number: 760-603-7229
Web Site: http://www.invitrogen.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Rabbit Anti-Aph-1aL, S Loop (92-115) Polyclonal Antibody, Unconjugated from Covance Research Products, Inc
2. Rabbit Anti-Human Vitamin K-dependent Protein S (PROS1) Polyclonal Antibody, Unconjugated from Lifespan Biosciences
3. Rabbit Anti-Human Sirtuin (silent mating type information regulation 2, S.cerevisiae, homolog) 7 (SIRT7) Polyclonal Antibody, Unconjugated from Lifespan Biosciences
4. Rabbit Anti-Esa1 Polyclonal Antibody, Unconjugated from Abcam
5. Rabbit Anti-Human Rad51 Polyclonal Antibody, Unconjugated from Abcam
6. Human CALCA EIA (Enzyme immunoassay) Kit, Host: Rabbit ; Extraction-free from BACHEM
7. MaxArray Tissue Array (Animal - Rabbit) from Invitrogen
8. Rabbit Anti-GST Polyclonal Antibody, Unconjugated from Novus Biologicals
9. Rabbit Anti-Shigella Polyclonal Antibody, Unconjugated from GeneTex
10. Vaginal Keratinocyte Progenitors, Rabbit from CHEMICON
11. Dermal Fibroblasts, Rabbit from CHEMICON
Breaking Biology News(10 mins):$2.4 million stimulus fuels effort to regenerate injured spinal cords 2$2.4 million stimulus fuels effort to regenerate injured spinal cords 3$2.4 million stimulus fuels effort to regenerate injured spinal cords 4Springer signs co-publishing agreement with the Royal Swedish Academy of Sciences 2List of 'unsung' wildlife affected by climate change released 2XRC Medical Imaging Announces Rapid Test Results 14182 1XRC Medical Imaging Announces Rapid Test Results 14182 2Abbotts XIENCE V 28R 29 Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long Term Safety Results in SPIRIT III Trial 5024 1Abbotts XIENCE V 28R 29 Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long Term Safety Results in SPIRIT III Trial 5024 2Abbotts XIENCE V 28R 29 Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long Term Safety Results in SPIRIT III Trial 5024 3Abbotts XIENCE V 28R 29 Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long Term Safety Results in SPIRIT III Trial 5024 4Abbotts XIENCE V 28R 29 Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long Term Safety Results in SPIRIT III Trial 5024 5Abbotts XIENCE V 28R 29 Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long Term Safety Results in SPIRIT III Trial 5024 6Dalton Pharma Services Adds Formulation Development Services 57793 1Dalton Pharma Services Adds Formulation Development Services 57793 2
Breaking Biology Technology:Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 2BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4